Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Custom-made Ceramic Barrier vs Titanium Mesh

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03734094
Recruitment Status : Completed
First Posted : November 7, 2018
Last Update Posted : December 21, 2018
Sponsor:
Information provided by (Responsible Party):
Mohamed El Saharty, Cairo University

Brief Summary:
It is a comparative study between custom-made ceramic barrier and titanium mesh for augmentation of atrophic posterior mandible.

Condition or disease Intervention/treatment Phase
Bone Loss Device: Ceramic barrier Device: Titanium Mesh Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 14 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Comparative Study Between Custom-made Ceramic Barrier and Titanium Mesh for Augmentation of Atrophic Posterior Mandible
Actual Study Start Date : July 1, 2018
Actual Primary Completion Date : July 1, 2018
Actual Study Completion Date : July 1, 2018

Arm Intervention/treatment
Experimental: Ceramic Barrier
The use of a ceramic barrier to induce bone formation during GBR
Device: Titanium Mesh
The use of a titanium mesh to induce bone formation during GBR

Active Comparator: Titanium mesh
The use of a titanium mesh to induce bone formation during GBR
Device: Ceramic barrier
The use of a ceramic barrier to induce bone formation during GBR




Primary Outcome Measures :
  1. Bone height [ Time Frame: 6 months ]
    CBCT & Three dimensional planning software to measure the height of bone gained in millimeters.

  2. Bone width [ Time Frame: 6 months ]
    CBCT & Three dimensional planning software to measure the width of bone gained in millimeters.


Secondary Outcome Measures :
  1. Histomorphometric - bone area percent [ Time Frame: 6 months ]
    Histomorphometric analysis of bone area percent



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Patients with atrophic posterior mandible
  • Both sexes
  • No intraoral soft and hard tissue pathology
  • No systemic condition that contraindicate implant placement

Exclusion Criteria:

  • Untreated gingivitis
  • Periodontitis
  • Insufficient oral hygiene
  • Previous radiation therapy
  • Head and neck neoplasia
  • Systemic disorders
  • Heavy smokers
  • Bone pathology
  • Psychiatric problems
  • Emotional instability
  • Unrealistic aesthetic demands

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03734094


Locations
Layout table for location information
Egypt
Cairo University
Cairo, Egypt, 12611
Sponsors and Collaborators
Cairo University
Layout table for additonal information
Responsible Party: Mohamed El Saharty, Principal Investigator, Cairo University
ClinicalTrials.gov Identifier: NCT03734094    
Other Study ID Numbers: 737
First Posted: November 7, 2018    Key Record Dates
Last Update Posted: December 21, 2018
Last Verified: December 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No